Milan, January 27, 2012– In relation to its share buy-back program, Sorin Group (Reuters Code: SORN.MI), a global leader in the treatment of cardiovascular diseases, announces that it has purchased on19^thJanuary, 2012 a total of 100,000 ordinary Sorin S.p.A. shares, equivalent to 0.0209% of the share capital, at an average unit gross price (including fees) of  Euro 1.3070 per share, for a total consideration of  Euro 130,700.
As of today, Sorin Group owns therefore n. 3,773,600 own shares, corresponding to 0.7882% of the share capital.

*  *  *

About Sorin Group
 
Sorin Group (www.sorin.com) is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,700 employees worldwide, Sorin Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management and heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.
  
For more information, please visit: www.sorin.com, or contact:

.pdf